They found that the chemo-preventive effects of statins achieved by targeting CCR1-dependent AM-like TAMs could be cancelled when continuously dosed in advanced cancers, leading to TAM replacement with monocyte-derived populations and accompanied by robust re-organization of the tumour immune microenvironment (Kamata et al., 2022). Here, CCR1 is linked to neoplasm.